Urological Cancer Market Growth, Size, Share and Forecast to 2021

Global Urological Cancer Market to 2022 - Strong Growth Driven by Rising Prevalence, Increased Uptake of Hormone Therapies and Approval of Novel Biologics
Global Urological Cancers Market Will Double to $35.9 billion by 2022, says GBI Research
The urological cancers market, including bladder, kidney, prostate and testicular cancer, will increase from $17.9 billion in 2015 to $35.9 billion by 2022, at a substantial compound annual growth rate of 10.39%, according to business intelligence provider GBI Research.
The companys latest report* states that this strong market growth will be driven by the predicted emergence of targeted therapies for bladder cancer and increasing prostate and kidney cancer prevalence.

Adam Bradbury, Analyst for GBI Research, explains: “The development and approval of immune checkpoint inhibitors will lower the associated toxicity of urological cancer therapies and increase their usage in typically poor-performance patients, who have a reduced functional status. Targeted treatment administration will increase patients’ overall survival and enable more rounds of chemotherapy to be given.

Browse full report with TOC@ https://marketreportscenter.com/reports/330416/global-urological-cancer-market-to-2022-strong-growth-driven-by-rising-prevalence-increased-uptake-of-hormone-therapies-and-approval-of-novel-biologics

It is predicted that two new urological cancer drugs for the treatment of bladder cancer – Roche’s atezolizumab and AstraZenecas durvalumab – will achieve blockbuster status by 2022. The former is anticipated to achieve revenue of $2.5 billion in 2022, following approval from late 2016, and its uptake will be driven by a lack of targeted therapies for bladder cancer, along with increasing prevalence and clinician familiarity.

The latter is anticipated to generate $1.2 billion in 2022, following its expected approval in 2017. It is expected to be one of an increasing number of cancer immunotherapies for bladder cancer,...